{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:32:01Z","timestamp":1760239921633,"version":"build-2065373602"},"reference-count":74,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.rdc.2023.01.003","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T22:08:34Z","timestamp":1680732514000},"page":"249-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Scleroderma Skin"],"prefix":"10.1016","volume":"49","author":[{"given":"Madelon C.","family":"Vonk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shervin","family":"Assassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10103","key":"10.1016\/j.rdc.2023.01.003_bib1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.rdc.2023.01.003_bib2","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"Classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.003_bib3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semarthrit.2016.02.005","article-title":"Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey","volume":"46","author":"Frantz","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.rdc.2023.01.003_bib4","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","article-title":"Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)","volume":"76","author":"Herrick","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.rdc.2023.01.003_bib5","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","article-title":"Severe organ involvement in systemic sclerosis with diffus scleroderma","volume":"43","author":"Steen","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2023.01.003_bib6","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.003_bib7","doi-asserted-by":"crossref","first-page":"e000826","DOI":"10.1136\/rmdopen-2018-000826","article-title":"Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features","volume":"5","author":"Hoffmann-Vold","year":"2019","journal-title":"RMD Open"},{"issue":"7","key":"10.1016\/j.rdc.2023.01.003_bib8","first-page":"1281","article-title":"Inter and Intraobserver Variability of Total Skin Thickness Score (Modified Rodnan Tss) in Systemic-Sclerosis","volume":"22","author":"Clements","year":"1995","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.003_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J\u00a0Scleroderma Relat Disord"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.003_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13075-019-1809-y","article-title":"Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)","volume":"21","author":"Khanna","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.rdc.2023.01.003_bib11","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/annrheumdis-2014-205226","article-title":"Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database","volume":"74","author":"Maurer","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2023.01.003_bib12","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1002\/art.24681","article-title":"Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: Analysis of three large multicenter, double-blind, randomized controlled trials","volume":"60","author":"Amjadi","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"SI","key":"10.1016\/j.rdc.2023.01.003_bib13","doi-asserted-by":"crossref","first-page":"SI54","DOI":"10.1093\/rheumatology\/keac363","article-title":"Late Skin Fibrosis in Systemic Sclerosis: A Study from the EUSTAR Cohort","volume":"62","author":"Hughes","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.003_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13075-020-2113-6","article-title":"Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis","volume":"22","author":"Ledoult","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.003_bib15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/ard.2009.127621","article-title":"Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma","volume":"70","author":"Domsic","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2023.01.003_bib16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/annrheumdis-2018-213455","article-title":"Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort","volume":"78","author":"Wu","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.rdc.2023.01.003_bib17","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1002\/1529-0131(200112)44:12<2828::AID-ART470>3.0.CO;2-U","article-title":"Improvement in skin thickening in systemic sclerosis associated with improved survival","volume":"44","author":"Steen","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.rdc.2023.01.003_bib18","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/rheumatology\/kez529","article-title":"Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis","volume":"59","author":"Nevskaya","year":"2020","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.rdc.2023.01.003_bib19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.39501","article-title":"The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis","volume":"68","author":"Khanna","year":"2016","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2023.01.003_bib20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2020-219100","article-title":"New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis","volume":"80","author":"Khanna","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2023.01.003_bib21","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/art.23564","article-title":"Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial","volume":"59","author":"Merkel","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.003_bib22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s42358-020-00152-6","article-title":"Durometry as an alternative tool to the modified Rodnan's skin score in the assessment of diffuse systemic sclerosis patients: a cross-sectional study","volume":"60","author":"de Oliveira","year":"2020","journal-title":"Adv Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2023.01.003_bib23","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/rheumatology\/keg435","article-title":"Seventeen-point dermal ultrasound scoring system--a reliable measure of skin thickness in patients with systemic sclerosis","volume":"42","author":"Moore","year":"2003","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.003_bib24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/rheumatology\/kem307","article-title":"High-frequency ultrasound of skin involvement in systemic sclerosis reflects oedema, extension and severity in early disease","volume":"47","author":"Hesselstrand","year":"2008","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.rdc.2023.01.003_bib25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3899\/jrheum.140873","article-title":"A\u00a0preliminary study of acoustic radiation force impulse quantification for the assessment of skin in diffuse cutaneous systemic sclerosis","volume":"42","author":"Hou","year":"2015","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.003_bib26","doi-asserted-by":"crossref","first-page":"151954","DOI":"10.1016\/j.semarthrit.2022.151954","article-title":"Ultrasound and elastography in the assessment of skin involvement in systemic sclerosis: A systematic literature review focusing on validation and standardization - WSF Skin Ultrasound Group","volume":"52","author":"Santiago","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2023.01.003_bib27","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3899\/jrheum.200234","article-title":"High frequency ultrasound assessment of systemic sclerosis skin involvement: intra-observer repeatability and relationship with clinician assessment and dermal collagen content","volume":"48","author":"Flower","year":"2020","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.003_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13075-017-1270-8","article-title":"Subclinical dermal involvement is detectable by high frequency ultrasound even in patients with limited cutaneous systemic sclerosis","volume":"19","author":"Sulli","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.rdc.2023.01.003_bib29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/cxo.12847","article-title":"An evidence-based approach to the routine use of optical coherence tomography","volume":"102","author":"Ly","year":"2019","journal-title":"Clin Exp Optom"},{"issue":"3","key":"10.1016\/j.rdc.2023.01.003_bib30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/annrheumdis-2016-210875","article-title":"Optical coherence tomography as a method for quantitative skin evaluation in systemic sclerosis","volume":"77","author":"Pires","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.rdc.2023.01.003_bib31","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1136\/annrheumdis-2012-202682","article-title":"Virtual skin biopsy by optical coherence tomography: the first quantitative imaging biomarker for scleroderma","volume":"72","author":"Abignano","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.rdc.2023.01.003_bib32","article-title":"Translational optical coherence elastography for assessment of systemic sclerosis","volume":"12","author":"Liu","year":"2019","journal-title":"J\u00a0Biophotonics"},{"issue":"4","key":"10.1016\/j.rdc.2023.01.003_bib33","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/art.1780210404","article-title":"Collagen in the cellular and fibrotic stages of scleroderma","volume":"21","author":"Fleischmajer","year":"1978","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2023.01.003_bib34","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41584-022-00765-9","article-title":"Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need","volume":"18","author":"Herrick","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.003_bib35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.rdc.2023.01.003_bib36","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"26","key":"10.1016\/j.rdc.2023.01.003_bib37","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.rdc.2023.01.003_bib38","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2023.01.003_bib39","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/acr2.11165","article-title":"Enrichment Strategy for Systemic Sclerosis Clinical Trials Targeting Skin Fibrosis: A Prospective, Multiethnic Cohort Study","volume":"2","author":"Mihai","year":"2020","journal-title":"ACR Open Rheumatology"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.003_bib40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2023.01.003_bib41","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2017-211912","article-title":"Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study","volume":"77","author":"Herrick","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.rdc.2023.01.003_bib42","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1093\/rheumatology\/keac188","article-title":"Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort","volume":"61","author":"Zanatta","year":"2022","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.rdc.2023.01.003_bib43","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1136\/annrheumdis-2015-208024","article-title":"Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis","volume":"75","author":"Dobrota","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.rdc.2023.01.003_bib44","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1093\/rheumatology\/keab075","article-title":"Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design","volume":"60","author":"Domsic","year":"2021","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.rdc.2023.01.003_bib45","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/14397595.2020.1784548","article-title":"Initial predictors of skin thickness progression in patients with diffuse cutaneous systemic sclerosis: Results from a multicentre prospective cohort in Japan","volume":"31","author":"Kuwana","year":"2021","journal-title":"Mod Rheumatol"},{"issue":"21","key":"10.1016\/j.rdc.2023.01.003_bib46","doi-asserted-by":"crossref","first-page":"12319","DOI":"10.1073\/pnas.1635114100","article-title":"Systemic and cell type-specific gene expression patterns in scleroderma skin","volume":"100","author":"Whitfield","year":"2003","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"11","key":"10.1016\/j.rdc.2023.01.003_bib47","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1002\/art.39289","article-title":"Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis","volume":"67","author":"Assassi","year":"2015","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2023.01.003_bib48","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/1529-0131(200106)44:6<1363::AID-ART229>3.0.CO;2-5","article-title":"Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis","volume":"44","author":"Asano","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2023.01.003_bib49","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/annrheumdis-2019-215894","article-title":"Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile","volume":"79","author":"Skaug","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2023.01.003_bib50","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2021-221352","article-title":"Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time","volume":"81","author":"Skaug","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2023.01.003_bib51","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2018-214778","article-title":"Compendium of skin molecular signatures identifies key pathological features associated with fibrosis in systemic sclerosis","volume":"78","author":"Moon","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2023.01.003_bib52","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/art.40455","article-title":"Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis","volume":"70","author":"Stifano","year":"2018","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.rdc.2023.01.003_bib53","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/art.40898","article-title":"A\u00a0Machine Learning Classifier for Assigning Individual Patients with Systemic Sclerosis to Intrinsic Molecular Subsets","volume":"71","author":"Franks","year":"2019","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.003_bib54","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2023.01.003_bib55","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1002\/art.39287","article-title":"A\u00a0Longitudinal Biomarker for the Extent of Skin Disease in Patients with Diffuse Cutaneous Systemic Sclerosis","volume":"67","author":"Rice","year":"2015","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.rdc.2023.01.003_bib56","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nrrheum.2014.137","article-title":"Transforming growth factor beta--at the centre of systemic sclerosis","volume":"10","author":"Lafyatis","year":"2014","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.003_bib57","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1038\/s41467-021-24607-6","article-title":"Myofibroblast transcriptome indicates SFRP2(hi) fibroblast progenitors in systemic sclerosis skin","volume":"12","author":"Tabib","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.rdc.2023.01.003_bib58","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/art.27220","article-title":"A\u00a0four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis","volume":"62","author":"Farina","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.rdc.2023.01.003_bib59","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J\u00a0Clin Invest"},{"issue":"Suppl 113","key":"10.1016\/j.rdc.2023.01.003_bib60","first-page":"146","article-title":"Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I\/II biomarker trial","volume":"36","author":"Mantero","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2023.01.003_bib61","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.jid.2017.06.032","article-title":"Inhibition of beta-Catenin Signaling in the Skin Rescues Cutaneous Adipogenesis in Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial of C-82","volume":"137","author":"Lafyatis","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.003_bib62","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13075-021-02633-5","article-title":"Multiomic study of skin, peripheral blood, and serum: is serum proteome a reflection of disease process at the end-organ level in systemic sclerosis?","volume":"23","author":"Farutin","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.rdc.2023.01.003_bib63","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/art.41570","article-title":"Large-scale characterization of systemic sclerosis serum protein profile: Comparison to peripheral blood cell transcriptome and correlations with skin\/lung fibrosis","volume":"73","author":"Bellocchi","year":"2020","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.003_bib64","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jid.2016.08.027","article-title":"A\u00a0Proteome-Derived Longitudinal Pharmacodynamic Biomarker for Diffuse Systemic Sclerosis Skin","volume":"137","author":"Rice","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"10.1016\/j.rdc.2023.01.003_bib65","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24\u00a0week randomized double-blind trial, followed by a 24\u00a0week observational trial","volume":"35","author":"VandenHoogen","year":"1996","journal-title":"Br J Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2023.01.003_bib66","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A\u00a0randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.rdc.2023.01.003_bib67","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease2","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.rdc.2023.01.003_bib68","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"24","key":"10.1016\/j.rdc.2023.01.003_bib69","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.003_bib70","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.rdc.2023.01.003_bib71","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/annrheumdis-2020-217058","article-title":"Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study","volume":"79","author":"van Bijnen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.rdc.2023.01.003_bib72","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","article-title":"A\u00a0randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis","volume":"79","author":"Allanore","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"10.1016\/j.rdc.2023.01.003_bib73","first-page":"1596","article-title":"Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"381","author":"Distler","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.rdc.2023.01.003_bib74","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/art.41294","article-title":"Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis","volume":"72","author":"Spiera","year":"2020","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X23000030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X23000030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:32:21Z","timestamp":1760182341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X23000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0889857X23000030"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2023.01.003","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scleroderma Skin","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2023.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}